NO329160B1 - Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning - Google Patents
Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning Download PDFInfo
- Publication number
- NO329160B1 NO329160B1 NO20045070A NO20045070A NO329160B1 NO 329160 B1 NO329160 B1 NO 329160B1 NO 20045070 A NO20045070 A NO 20045070A NO 20045070 A NO20045070 A NO 20045070A NO 329160 B1 NO329160 B1 NO 329160B1
- Authority
- NO
- Norway
- Prior art keywords
- fdg
- solution
- glucose
- deoxy
- buffer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 239000000872 buffer Substances 0.000 claims abstract description 39
- 239000002253 acid Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 44
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 36
- 229940072107 ascorbate Drugs 0.000 claims description 18
- 235000010323 ascorbic acid Nutrition 0.000 claims description 18
- 239000011668 ascorbic acid Substances 0.000 claims description 18
- 239000007979 citrate buffer Substances 0.000 claims description 13
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 239000008351 acetate buffer Substances 0.000 claims description 5
- 238000003608 radiolysis reaction Methods 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000013074 reference sample Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005395 radioluminescence Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/04—Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02076638A EP1356827A1 (en) | 2002-04-24 | 2002-04-24 | Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution |
| PCT/US2003/012603 WO2003090789A1 (en) | 2002-04-24 | 2003-04-23 | Method for obtaining a 2-18f-fluor-2-deoxy-d-glucose (18f-fdg) - solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20045070L NO20045070L (no) | 2004-11-22 |
| NO329160B1 true NO329160B1 (no) | 2010-08-30 |
Family
ID=28685968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045070A NO329160B1 (no) | 2002-04-24 | 2004-11-22 | Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8182788B2 (ja) |
| EP (2) | EP1356827A1 (ja) |
| JP (2) | JP5132869B2 (ja) |
| KR (1) | KR20050005456A (ja) |
| CN (1) | CN1323724C (ja) |
| AT (1) | ATE422903T1 (ja) |
| AU (1) | AU2003225124B2 (ja) |
| CA (1) | CA2483181C (ja) |
| DE (1) | DE60326220D1 (ja) |
| IL (2) | IL164805A0 (ja) |
| NO (1) | NO329160B1 (ja) |
| PL (1) | PL371682A1 (ja) |
| WO (1) | WO2003090789A1 (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422004D0 (en) * | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
| CA2610252A1 (en) * | 2005-06-14 | 2006-12-21 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
| WO2007148083A2 (en) * | 2006-06-21 | 2007-12-27 | Ge Healthcare As | Stabilisation of radiopharmaceutical precursors |
| WO2007148755A1 (ja) * | 2006-06-21 | 2007-12-27 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物 |
| US20100056826A1 (en) * | 2006-11-09 | 2010-03-04 | Nihon Medi-Physicis Co., Ltd. | Radioactive diagnostic imaging agent |
| US8790620B2 (en) * | 2006-12-21 | 2014-07-29 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| TWI406674B (zh) | 2007-02-13 | 2013-09-01 | Nihon Mediphysics Co Ltd | Method for manufacturing diagnostic radiographic diagnostic agents |
| CA2703649A1 (en) * | 2007-10-24 | 2009-04-30 | Shigeyuki Tanifuji | Novel compound having affinity for amyloid |
| US20100267952A1 (en) * | 2007-10-30 | 2010-10-21 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
| US20100216994A1 (en) * | 2007-10-30 | 2010-08-26 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
| RU2474435C2 (ru) * | 2007-11-07 | 2013-02-10 | Джи-И Хелткер БВ | Стабилизация радиофармацевтических композиций |
| KR101602992B1 (ko) | 2009-04-15 | 2016-03-11 | 랜티우스 메디컬 이메징, 인크. | 아스코르브산을 사용한 방사성 약제 조성물의 안정화 |
| ES2785990T3 (es) * | 2010-08-13 | 2020-10-08 | Siemens Medical Solutions Usa Inc | Formulación, aparato y método para estabilizar productos radiofarmacéuticos |
| KR20130132892A (ko) | 2010-12-29 | 2013-12-05 | 지이 헬쓰케어 리미티드 | 용리제 용액 |
| US20130004414A1 (en) * | 2011-06-30 | 2013-01-03 | General Electric Company | Devices and methods for reducing radiolysis of radioisotopes |
| US20130005958A1 (en) * | 2011-06-30 | 2013-01-03 | General Electric Company | Devices and methods for reducing radiolysis of radioisotopes |
| US11534494B2 (en) | 2011-12-21 | 2022-12-27 | Ge Healthcare Limited | Formulation and method of synthesis |
| GB201411569D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Novel formulation and method of synthesis |
| GB2509476B (en) * | 2011-12-21 | 2018-08-08 | Ge Healthcare Ltd Ip | 18F - Fluciclovine compositions in citrate buffers |
| GB201202420D0 (en) * | 2012-02-13 | 2012-03-28 | Ge Healthcare Ltd | Radiotracer compositions |
| FR3054445B1 (fr) * | 2016-07-26 | 2019-07-05 | Laboratoires Cyclopharma | Synthese d'une composition d'agent radioactif |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707353A (en) * | 1982-12-08 | 1987-11-17 | Mallinckrodt, Inc. | Radiographic imaging agents |
| SE9002117L (sv) * | 1990-06-14 | 1991-08-26 | Nils Elander | Mikrovaagsanordning foer behandling av precessvaetskor |
| DE69133514T2 (de) | 1990-07-06 | 2006-09-28 | Mallinckrodt, Inc. | Verfahren zur herstellung einer lösung eines radioaktiven rhenium-komplexes |
| JPH0797340A (ja) * | 1993-06-03 | 1995-04-11 | Terumo Corp | Ｍｒｉ造影剤組成物 |
| BE1010280A3 (fr) | 1996-05-02 | 1998-05-05 | Coincidence S A | Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose. |
| IL129263A0 (en) * | 1996-10-07 | 2000-02-17 | Du Pont Merck Pharma | Radiopharmaceuticals for imaging infection and inflammation |
-
2002
- 2002-04-24 EP EP02076638A patent/EP1356827A1/en not_active Withdrawn
-
2003
- 2003-04-23 CA CA2483181A patent/CA2483181C/en not_active Expired - Lifetime
- 2003-04-23 AT AT03721834T patent/ATE422903T1/de not_active IP Right Cessation
- 2003-04-23 PL PL03371682A patent/PL371682A1/xx not_active IP Right Cessation
- 2003-04-23 AU AU2003225124A patent/AU2003225124B2/en not_active Ceased
- 2003-04-23 IL IL16480503A patent/IL164805A0/xx unknown
- 2003-04-23 DE DE60326220T patent/DE60326220D1/de not_active Expired - Lifetime
- 2003-04-23 WO PCT/US2003/012603 patent/WO2003090789A1/en active Search and Examination
- 2003-04-23 JP JP2003587417A patent/JP5132869B2/ja not_active Expired - Lifetime
- 2003-04-23 EP EP03721834A patent/EP1496946B1/en not_active Expired - Lifetime
- 2003-04-23 US US10/510,454 patent/US8182788B2/en active Active
- 2003-04-23 CN CNB03809035XA patent/CN1323724C/zh not_active Expired - Fee Related
- 2003-04-23 KR KR10-2004-7016968A patent/KR20050005456A/ko active IP Right Grant
-
2004
- 2004-10-25 IL IL164805A patent/IL164805A/en active IP Right Grant
- 2004-11-22 NO NO20045070A patent/NO329160B1/no not_active IP Right Cessation
-
2010
- 2010-07-29 JP JP2010171216A patent/JP2010248244A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO20045070L (no) | 2004-11-22 |
| US20050175536A1 (en) | 2005-08-11 |
| CA2483181C (en) | 2011-06-28 |
| AU2003225124A1 (en) | 2003-11-10 |
| JP5132869B2 (ja) | 2013-01-30 |
| IL164805A0 (en) | 2005-12-18 |
| JP2006500319A (ja) | 2006-01-05 |
| IL164805A (en) | 2009-06-15 |
| WO2003090789A1 (en) | 2003-11-06 |
| CN1646175A (zh) | 2005-07-27 |
| EP1496946A1 (en) | 2005-01-19 |
| CN1323724C (zh) | 2007-07-04 |
| KR20050005456A (ko) | 2005-01-13 |
| PL371682A1 (en) | 2005-06-27 |
| JP2010248244A (ja) | 2010-11-04 |
| US8182788B2 (en) | 2012-05-22 |
| EP1356827A1 (en) | 2003-10-29 |
| EP1496946B1 (en) | 2009-02-18 |
| ATE422903T1 (de) | 2009-03-15 |
| CA2483181A1 (en) | 2003-11-06 |
| AU2003225124B2 (en) | 2007-06-14 |
| DE60326220D1 (de) | 2009-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329160B1 (no) | Fremgangsmate for a frembringe en 2-18F-fluor-2-deoksy-D-glukose(18F-FDG)-losning | |
| CN109384806B (zh) | 一种[18f]fbpa新型制备方法 | |
| KR102459213B1 (ko) | 카르글룸산을 함유하는 약제학적 비경구 제형 | |
| NO340538B1 (no) | Flerdose, ikke-radioaktivt sett som ved rekonstituering med 99mTc-pertechnetatløsning gir en stabilisert radiofarmasøytisk 99mTc-tetrofosminsammensetning og fremgangsmåter for fremstilling | |
| CN102397245A (zh) | 一种盐酸尼卡地平葡萄糖注射液 | |
| US3812245A (en) | Novel compositions for radiotracer localization of deep vein thrombi | |
| NO343137B1 (no) | Radioaktivt diagnostisk avbildningsmiddel | |
| JP2009229201A (ja) | Ｇａのイオンを単離する方法とそのための装置 | |
| JP5112062B2 (ja) | 放射性画像診断剤 | |
| CN107198780A (zh) | 放射性药物组合物及其制备方法、应用 | |
| EP1958954A1 (en) | Process for production of compound labeled with radioactive fluorine | |
| CN101683320A (zh) | 一种盐酸奥普立农注射液及其制备方法 | |
| JP4649084B2 (ja) | テクネチウムＴｃ９９ｍテボロキシム心筋灌流剤の調製のためのキット | |
| KR101850479B1 (ko) | [18F]플루오로-도파의 중성 pH 안정화 방법 | |
| Smith et al. | Radioprotective action of methoxamine | |
| Richards et al. | Synthesis of [18F]‐Fluorodeoxyglucose ([18F] FDG) | |
| RU2793921C1 (ru) | Способ получения лиофилизованного препарата bpa | |
| Tsai et al. | Comparison of [N-13] NH3 Production Methods: Practical Experience of National Taiwan University Hospital | |
| WO2024206285A2 (en) | Enzymatic radiosynthesis of deoxy-[18f]fluorocellobiose and deoxy-[18f]fluorocellotriose | |
| Shaeffer | Lack of enhanced lysis of fibrinogen-I131 by anticoagulants in tumor-bearing rats | |
| Goethals et al. | Synthesis of 6-methyl [11C]-2′-deoxyuridine and evaluation of its in vivo distribution in Wistar rats | |
| EP1977769A1 (en) | Kit for the preparation of a radioactive iodine marker comprising lyophilized meta-iodobenzyl guanidine (MIBG), a method of preparation thereof and a method of radiolabelling said MIBG. | |
| Haley et al. | Effect of histamine and antihistaminics on coagulation of normal and heparinized rabbit plasma | |
| JP5105343B2 (ja) | 局所脳血流診断用放射性医薬品 | |
| Di Carlo et al. | Prolactin binding sites in human brain and choroid plexus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |